Pasithea Therapeutics (NASDAQ:KTTA) Posts Quarterly Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) issued its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, FiscalAI reports.

Pasithea Therapeutics Stock Up 2.1%

Shares of NASDAQ KTTA traded up $0.01 during trading on Friday, reaching $0.72. The company had a trading volume of 112,653 shares, compared to its average volume of 88,943. Pasithea Therapeutics has a 12-month low of $0.65 and a 12-month high of $3.85. The business’s 50-day moving average is $0.75 and its 200 day moving average is $0.81. The stock has a market cap of $5.34 million, a PE ratio of -0.14 and a beta of 0.29.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Pasithea Therapeutics

A hedge fund recently raised its stake in Pasithea Therapeutics stock. AdvisorShares Investments LLC grew its position in Pasithea Therapeutics Corp. (NASDAQ:KTTA) by 261.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 193,547 shares of the company’s stock after buying an additional 140,000 shares during the period. AdvisorShares Investments LLC owned approximately 2.60% of Pasithea Therapeutics worth $140,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 23.92% of the company’s stock.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.